226 related articles for article (PubMed ID: 17691275)
1. Lipid-lowering drugs: use and expenditure in Portugal (1995-2004).
Teixeira IJ; Escoval A; Schiappa M
Rev Port Cardiol; 2007 May; 26(5):475-93. PubMed ID: 17691275
[TBL] [Abstract][Full Text] [Related]
2. Anti-hypertensive drug utilization in Continental Portugal (1999-2004).
Furtado C; Pinto M
Rev Port Cardiol; 2006 Mar; 25(3):273-92. PubMed ID: 16789402
[TBL] [Abstract][Full Text] [Related]
3. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003.
Walley T; Folino-Gallo P; Stephens P; Van Ganse E
Br J Clin Pharmacol; 2005 Nov; 60(5):543-51. PubMed ID: 16236045
[TBL] [Abstract][Full Text] [Related]
4. Spending on medicines in Israel in an international context.
Sax P
Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459
[TBL] [Abstract][Full Text] [Related]
5. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future.
Godman B; Burkhardt T; Bucsics A; Wettermark B; Wieninger P
Expert Rev Pharmacoecon Outcomes Res; 2009 Oct; 9(5):475-84. PubMed ID: 19817531
[TBL] [Abstract][Full Text] [Related]
6. Pharmacoeconomics of lipid lowering therapy in Ireland.
Barry M; Heerey A; Sheehan O; Ryan M; McCulloch D; Feely J
Ir Med J; 1999; 92(7):430-2. PubMed ID: 10967865
[TBL] [Abstract][Full Text] [Related]
7. Development of indicators for assessing the quality of prescribing of lipid-lowering drugs: data from the pharmacotherapeutic quality circles in Hesse, Germany.
Schubert ; Köster ; Ihle P; von Ferber L
Int J Clin Pharmacol Ther; 2001 Nov; 39(11):492-8. PubMed ID: 11727970
[TBL] [Abstract][Full Text] [Related]
8. [Cost of cancer care in Portugal].
Araújo A; Barata F; Barroso S; Cortes P; Damasceno M; Parreira A; Espírito Santo J; Teixeira E; Pereira R
Acta Med Port; 2009; 22(5):525-36. PubMed ID: 19944035
[TBL] [Abstract][Full Text] [Related]
9. [Benzodiazepine's utilization in continental Portugal (1999-2003)].
Furtado C; Teixeira I
Acta Med Port; 2006; 19(3):239-46. PubMed ID: 17234086
[TBL] [Abstract][Full Text] [Related]
10. Expenditure and consumption of medicines in Israel 1975-85: analysis of trends and elements of growth.
Sax P
Isr J Med Sci; 1988 Jun; 24(6):307-16. PubMed ID: 3136096
[TBL] [Abstract][Full Text] [Related]
11. [Use of specific drugs for Alzheimer's disease].
Villar Fernández I; Rabaneque Hernández MJ; Armesto Gómez J; García Arilla E; Izuel Rami M
Neurologia; 2007 Jun; 22(5):275-84. PubMed ID: 17508301
[TBL] [Abstract][Full Text] [Related]
12. Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals.
Andersson K; Bergström G; Petzold MG; Carlsten A
Health Policy; 2007 May; 81(2-3):376-84. PubMed ID: 16945449
[TBL] [Abstract][Full Text] [Related]
13. Quantifying the use of the statin antilipemic drugs: comparisons and contrasts between Nova Scotia, Canada, and Queensland, Australia.
Cooke C; Nissen L; Sketris I; Tett SE
Clin Ther; 2005 Apr; 27(4):497-508. PubMed ID: 15922822
[TBL] [Abstract][Full Text] [Related]
14. [Use of hypolipemic agents in Spain, 1987-2000].
Siles Gutiérrez M; Goldaracena Tanco M; Avila Muñoz L; Sánchez-Eznarriaga BC
Rev Esp Salud Publica; 2001; 75(2):129-41. PubMed ID: 11400423
[TBL] [Abstract][Full Text] [Related]
15. [Efficiency versus quality in the NHS, in Portugal: methodologies for evaluation].
Giraldes Mdo R
Acta Med Port; 2008; 21(5):397-410. PubMed ID: 19187682
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
Mullins CD; Rattinger GB; Kuznik A; Koren MJ
Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
[TBL] [Abstract][Full Text] [Related]
17. Imperative to consider multiple initiatives to maximize prescribing efficiency from generic availability: case history from Abu Dhabi.
Abuelkhair M; Abdu S; Godman B; Fahmy S; Malmström RE; Gustafsson LL
Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):115-24. PubMed ID: 22280201
[TBL] [Abstract][Full Text] [Related]
18. Proton pump inhibitors and hospital discharge rates for gastrointestinal events in Italy: a national ecological study.
Russo P; Brutti C
Clin Ther; 2007 Apr; 29(4):751-8. PubMed ID: 17617299
[TBL] [Abstract][Full Text] [Related]
19. Drug usage by outpatients in Croatia during an 8-year period: Influence of changes in pricing policy.
Vitezic D; Madjarevic T; Gantumur M; Buble T; Vitezic M; Kovacevic M; Mrsic-Pelcic J; Sestan B
Int J Clin Pharmacol Ther; 2012 Jul; 50(7):483-9. PubMed ID: 22578201
[TBL] [Abstract][Full Text] [Related]
20. Trends in the supply and use of lipid-lowering drugs in Spain, 1983 through 1991.
De Abajo FJ; Madurga M; Montero D; Adin J; Palop R
Therapie; 1993; 48(2):145-9. PubMed ID: 8351684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
